XPOVIO Drug Patent Profile

Which patents cover Xpovio, and what generic alternatives are available?

Xpovio is a drug marketed by Karyopharm Theraps and is included in one NDA. There are eleven patents protecting this drug.

This drug has one hundred and thirty-six patent family members in thirty-nine countries.

The generic ingredient in XPOVIO is selinexor. One supplier is listed for this compound. Additional details are available on the selinexor profile page.

DrugPatentWatch^® Generic Entry Outlook for Xpovio

Xpovio was eligible for patent challenges on July 3, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 14, 2035. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for XPOVIO

International Patents:	136
US Patents:	11
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	47
Clinical Trials:	24
Patent Applications:	3,488
Drug Prices:	Drug price information for XPOVIO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XPOVIO
What excipients (inactive ingredients) are in XPOVIO?	XPOVIO excipients list
DailyMed Link:	XPOVIO at DailyMed

See drug prices for XPOVIO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XPOVIO

Constraining patent/regulatory exclusivity:

11,807,629

NDA:

212306

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XPOVIO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Miami	Phase 2
Xia Zhongjun	Phase 1/Phase 2
Li Zhiming	Phase 2

See all XPOVIO clinical trials

Pharmacology for XPOVIO

Drug Class	Nuclear Export Inhibitor
Mechanism of Action	Nuclear Export Inhibitors

US Patents and Regulatory Information for XPOVIO

XPOVIO is protected by twenty US patents and six FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 11,807,629.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-003	Apr 15, 2021		RX	Yes	No	11,753,401		Y
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-001	Jul 3, 2019		RX	Yes	No	9,714,226		Y	Y
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-001	Jul 3, 2019		RX	Yes	No	11,746,102
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-003	Apr 15, 2021		RX	Yes	No	9,714,226		Y	Y
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-006	Oct 20, 2025		RX	Yes	No	11,787,771
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-004	Apr 15, 2021		RX	Yes	Yes

EU/EMA Drug Approvals for XPOVIO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Stemline Therapeutics B.V.	Nexpovio	selinexor	EMEA/H/C/005127NEXPOVIO is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.	Authorised	no	no	no	2021-03-26

International Patents for XPOVIO

When does loss-of-exclusivity occur for XPOVIO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Colombia

Denmark

Eurasian Patent Organization

European Patent Office

Israel

Japan

Mexico

Morocco

New Zealand

Singapore

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XPOVIO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015301484
Australia	2020203246
Australia	2021286266
Australia	2024202835
Canada	2957266
China	107072992

Supplementary Protection Certificates for XPOVIO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2736887	301119	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME
2736887	PA2021007	Lithuania		PRODUCT NAME: SELINEKSORAS; REGISTRATION NO/DATE: EU/1/21/1537 20210326
2736887	CA 2021 00031	Denmark		PRODUCT NAME: SELINEXOR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1537 20210329
2736887	LUC00219	Luxembourg		PRODUCT NAME: SELINEXOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/21/1537 20210329
2736887	2021C/532	Belgium		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME
2736887	122021000055	Germany		PRODUCT NAME: SELINEXOR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1537 20210326

XPOVIO (selinexor) market dynamics and financial trajectory: revenue trend drivers, payer mix, channel structure, and exclusivity-driven competitive risks

Last updated: May 31, 2026

Executive summary
XPOVIO’s financial trajectory has been shaped by (1) a shift from pivotal single-agent/earlier combinations toward commercially scaled combination regimens in relapsed/refractory multiple myeloma (RRMM), (2) uptake constraints tied to tolerability and dose management, and (3) intensifying competitive pressure from line-of-therapy alternatives that compress net pricing. Upside cases are concentrated in regimen expansions and sustained formulary positioning after guideline adoption; downside cases concentrate in rapid price erosion if multiple new agents displace selinexor in later lines and if payer utilization management tightens after high WAC discounts.

---

What is XPOVIO’s market position in relapsed/refractory multiple myeloma (RRMM)?

XPOVIO (selinexor) is positioned as an oral selective inhibitor of nuclear export (XPO1) used in RRMM and, through broader development, adjacent hematologic indications. Commercially, its highest-impact market access has come through real-world adoption where it fits established multi-agent sequencing and can be supported by clear benefit-risk narratives.

Core market dynamics by demand driver

• Line-of-therapy dependency: XPOVIO’s commercial demand is line-of-therapy sensitive. It grows when it is pulled forward into regimens adopted by clinicians for earlier RRMM rather than reserved for late lines after multiple prior mechanisms.
• Tolerability and dose intensity: The need for supportive care (antiemetics, hematologic monitoring, electrolyte management) affects patient retention and prescriber confidence. That friction tends to slow penetration versus drugs with simpler oral dosing profiles.
• Regimen stickiness vs. substitution: When XPOVIO is used as part of a specific combination protocol, substitution risk falls because switching breaks established clinical routines and payer prior authorization logic.
• Payer utilization management: Formularies and prior authorization criteria can change quickly after usage data accumulates. Utilization control tends to cap volume growth even if prescriber interest is present.

---

How fast did XPOVIO scale commercially, and what drives acceleration or deceleration?

Acceleration factors

• Regimen expansion: Commercial uptake tends to accelerate after label-aligned evidence converts into broader guideline or consensus practice.
• Channel readiness: XPOVIO’s growth generally tracks the buildout of specialty distribution workflows: patient support programs, hub services, and co-pay assistance structures that reduce initiation delays.
• Improved tolerability protocols: Dose modification patterns that reduce discontinuations can lift effective patient persistence, which improves revenue stability.

Deceleration factors

• Net price compression: Increased access via broader discounting can drive volume, but it can also reduce revenue per unit. If competitor entry increases bargaining leverage, XPOVIO net prices trend down.
• Alternative mechanism substitution: In RRMM, new classes (BCMA-directed therapies, bispecifics, and additional non-XPO1 oral agents) can redirect patient cohorts away from older mechanisms.
• Prior authorization strictness: If payers tighten criteria after early adoption, the marginal demand curve flattens.

---

What is the financial trajectory for XPOVIO revenue, and how do investors usually underwrite it?

Underwriting framework used by market participants

1. Prescription penetration in RRMM: Measured indirectly via TRx (where available), market share, and clinician adoption curves.
2. Dose persistence: Revenue stability in oncology drugs is tightly correlated to persistence and adherence because treatment cycles drive consumption.
3. Net price and access economics: XPOVIO performance hinges on payer mix (commercial vs Medicare vs Medicaid), contract structures, and increasing discount intensity.
4. Guideline alignment: Uptake improves when therapy positioning is endorsed across major treatment frameworks for the relevant RRMM lines.

Revenue trajectory characteristics typical for XPOVIO

• Early growth is front-loaded on sentiment and evidence conversion but then transitions to persistence-dependent revenue once real-world discontinuations become measurable.
• Mid-cycle volatility often reflects payer contract cycles and competing product introductions rather than label-only changes.
• Late-cycle pressure comes when competitors establish preferred status in the same line-of-therapy segment.

---

How do payer mix and net pricing dynamics affect XPOVIO’s revenue trajectory?

XPOVIO’s net revenue depends on contract coverage and the degree of utilization management.

Payer and channel factors

• Specialty pharmacy capture: Specialty pharmacies typically mediate patient access and can influence ordering patterns through inventory behavior and reimbursement timing.
• Commercial rebate intensity: As payer leverage increases, rebate intensity typically rises, shifting revenue growth from unit growth to flat-to-declining net pricing.
• Medicare and dual-eligible exposure: Lower net pricing can slow revenue growth even when volume rises, depending on gross-to-net assumptions.
• Formulary tiering: If XPOVIO moves to less favorable formulary tiers, prior authorization frequency increases, which slows starts and compresses patient persistence.

Practical implication for forecasting

• A stable prescription base with falling net pricing can still deliver declining revenue.
• A rising prescription base with stable net pricing can deliver durable growth, but only if persistence remains acceptable.

---

Which competitive drugs most affect XPOVIO in RRMM, and how does that change its market dynamics?

XPOVIO faces competition across RRMM classes, with competitive intensity increasing as new mechanisms gain dominance.

Competition vectors

• Mechanism substitution in later lines: Therapies that produce higher response rates and more predictable toxicity profiles can displace XPOVIO, particularly in lines where outcomes are benchmarked heavily.
• Route and convenience: Oral convenience does not always win if supportive-care burden is higher. Drugs with lower grade burden can outcompete via better adherence.
• Combination protocols: When competing regimens become the default standard of care for a given RRMM line, clinicians have less incentive to maintain XPOVIO in combination sequences.

Effect on XPOVIO

• Unit growth can slow even if clinical interest remains, because payer policies and clinician preference shift.
• Net pricing can fall as manufacturers offer more aggressive access terms to maintain position.

---

How does XPOVIO’s exclusivity and patent estate shape generic or biosimilar risk?

XPOVIO is a small-molecule drug, so the principal risk is generic entry rather than biosimilars.

Exclusivity and patent risk mechanics

• Orange Book-driven timeline: Generic risk is constrained by unexpired composition-of-matter and method-of-use patents listed in the Orange Book and by any paediatric exclusivity or data exclusivity tied to the specific NDA approvals.
• Paragraph IV challenges: The practical generic threat accelerates if ANDA filers challenge relevant patents and settle or proceed on an at-risk basis.

Featured risk outcome profiles

• Settlement earlier than statutory triggers: Often leads to a delayed but well-defined generic entry schedule, usually with a branded market share “cliff” near the end of the protected window.
• Adverse litigation outcomes: Can lead to earlier entry, with steep pricing pressure after launch.
• Multiple protective patents: If the estate includes multiple claims, even if one is invalidated, remaining patents can sustain some form of launch delay through tailored carve-outs or design-around limits.

---

What is the Orange Book status of XPOVIO, and how many patents protect it?

A complete Orange Book status requires a product-level listing of patents and exclusivities for the exact NDA(s), including:

• patent numbers and listed claim types (composition vs method),
• expiration dates,
• whether any patents are “carved out” for generic entry.

This analysis cannot be completed without the underlying Orange Book listing data for XPOVIO’s specific NDA entries.

---

What patent litigation affects XPOVIO, and how does it impact commercial timing?

Patent litigation can shape revenue trajectory via:

• launch delay agreements that create predictable demand protection,
• at-risk launch scenarios that can create abrupt price declines,
• settlement scope that determines which dosage forms and indications are at issue.

A complete mapping of litigation requires docket-level and settlement-specific data for the XPOVIO patent estate and the involved ANDA filers.

---

How does XPOVIO compare with alternative RRMM regimens on adoption economics?

Adoption tends to follow three criteria

• evidence strength in the target RRMM line,
• tolerability burden and supportive-care requirements,
• payer acceptance as reflected in prior authorization rates and coverage breadth.

XPOVIO-specific economic profile

• Its economic adoption tends to be sensitive to the real-world feasibility of managing known AEs and the sustainability of dosing over multiple cycles.
• The more it is “standardized” into consistent combination pathways, the more predictable reimbursement and persistence become.
• Rapid replacement by newer agents in the same line of therapy tends to reduce the maximum addressable patient pool over time.

---

What formulation and method-of-use IP can delay generic entry for XPOVIO?

Small-molecule oncology IP can include:

• composition-of-matter coverage,
• crystalline form claims,
• formulation and stability claims,
• method-of-use or dosing regimen claims tied to therapeutic indication(s).

A full formulation/method-of-use protection map requires the exact Orange Book patent claims and their expiration dates, which are not provided in the available dataset.

---

How do channel economics and patient support programs influence XPOVIO financial performance?

Patient support programs affect time-to-treatment initiation and adherence, which in turn affects:

• monthly scripts and cycle counts,
• discontinuation rates due to access delays,
• real-world persistence.

Channel mechanics

• Hub services and co-pay support can lift initiation rates where reimbursement is uncertain.
• Specialty distribution ensures inventory continuity but can introduce ordering volatility when patients start later than expected due to prior authorization approvals.

---

When does XPOVIO face peak revenue risk from competitive entry?

Peak revenue risk typically concentrates at:

• the end of the last relevant exclusivity or patent barrier for the most commercially important dosage forms and indications,
• the post-launch phase when competing products gain formulary position and widen coverage.

A specific date-based risk window requires a complete expiration and exclusivity timeline for XPOVIO’s relevant patents and exclusivities.

---

Key Takeaways

• XPOVIO’s market dynamics are primarily driven by RRMM line-of-therapy placement, tolerability-managed persistence, and payer-driven net price compression.
• Revenue trajectory typically shifts from evidence conversion growth to persistence and access economics after early penetration.
• Competitive pressure in RRMM reduces volume and increases discount intensity, affecting net revenue even if gross demand remains stable.
• Generic entry risk for a small molecule is driven by Orange Book patent and exclusivity timelines, with litigation and settlement outcomes determining the shape of the commercial “cliff.”
• A full protection and date-specific generic risk assessment requires the exact Orange Book listing and litigation/settlement record for XPOVIO’s NDA(s).

---

FAQs

1. Does XPOVIO revenue depend more on new patient starts or on treatment persistence?
2. How do prior authorization criteria typically impact XPOVIO script volume in commercial plans?
3. What contractual mechanisms most commonly drive XPOVIO net price erosion in RRMM?
4. How do settlement terms in Paragraph IV cases change the timing of generic launch risk for small-molecule oncology drugs?
5. Which RRMM regimen shifts most often reduce the addressable patient pool for XPOVIO over time?

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Drugs@FDA: XPOVIO (selinexor). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
3. FDA. ANDA Paragraph IV Information. U.S. Food and Drug Administration. https://www.fda.gov/